Medical News

RSS

Salmonella bacteria found in garden birds are sensitive to antibiotics

Scientists at the University of Liverpool have found that Salmonella bacteria found in garden birds are sensitive to antibiotics, suggesting that the infection is unlike the bacteria found in livestock and humans.

2 Jun 2008

Ban all tobacco adverts says the WHO

May 31st was ' World No Tobacco Day' and the World Health Organisation (WHO) has used that as an opportunity to call on all governments to ban tobacco advertising.

2 Jun 2008

New breast cancer drug combo shrinks aggressive tumours

An international trial of a new breast cancer drug has shown the drug is able to shrink tumours caused by one of the most aggressive forms of the disease.

2 Jun 2008

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2008

DialysisPPO files provisional patent for dialysis cost containment

DialysisPPO, a Pennsylvania Corporation providing cost containment solutions to the health plan market, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering its business method that enables health plans to significantly lower their exposure to the high cost of dialysis services while simultaneously improving the benefits to plan participants.

2 Jun 2008

Mylan acquires generics businesses of Merck KGaA

Mylan Inc. today announced that it has acquired Merck KGaA's Central & Eastern Europe (CEE) generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic.

2 Jun 2008

Oncolytics Biotech announces results for intravenous Reolysin in patients with sarcomas metastatic to the lung

Oncolytics Biotech Inc. has announced that interim results of a Phase II study of intravenous Reolysin in patients with sarcomas metastatic to the lung were presented yesterday at the American Society of Clinical Oncology (ASCO) annual meeting.

2 Jun 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

Prime Healthcare to acquire three hospitals from Tenet Healthcare

Prime Healthcare Services has acquired the 151-bed Encino Campus of Encino-Tarzana Regional Medical Center from Tenet Healthcare Corporation ("Tenet") effective June 1 and will operate the hospital as Encino Hospital Medical Center.

2 Jun 2008

IDM Pharma presents new data on IDM-2101 in non-small cell lung cancer

IDM Pharma, Inc. today announced follow-up results from the Phase 2 study of IDM-2101 showing that the product candidate was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) who were treated with IDM-2101, compared to a parallel external control group of HLA-A2 negative non-treated patients.

2 Jun 2008

Watson receives approval of Omeprazole delayed-release capsules

Watson Pharmaceuticals, Inc. has announced today that it has received final approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Capsules USP in the 10mg, 20mg and 40mg strengths.

2 Jun 2008

BiPar Sciences presents data for novel DNA repair inhibitor

BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.

2 Jun 2008

Genta announces initial trial results for novel drug for bone disease

Genta Incorporated has announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.

2 Jun 2008

Royal seal of approval for Breakthrough Breast Cancer's world-class research unit in Edinburgh

A pioneering new breast cancer research unit set up by leading UK charity Breakthrough Breast Cancer and the University of Edinburgh will be officially opened on Thursday 5 June 2008 by HRH The Prince of Wales (also known as The Duke of Rothesay while travelling in Scotland), the charity's Patron.

2 Jun 2008

U.S. Patent Office confirms second of four Viread patents

Gilead Sciences, Inc. has announced that the U.S. Patent & Trademark Office (PTO) has completed the second of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 5,922,695, which covers the composition of matter for Viread (tenofovir disoproxil fumarate). On May 20, Gilead announced that the U.S. PTO confirmed the patentability of U.S. Patent No. 6,043,230.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

NIDA highlights best drug abuse treatment approaches at blending conference

The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.

2 Jun 2008

Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems

Adults who survived childhood Hodgkin's Lymphoma should be especially vigilant about cancer and cardiovascular screenings, according to researchers from Wake Forest University Baptist Medical Center and colleagues.

2 Jun 2008

3 million now receiving anti-retroviral therapy HIV drugs

The close of 2007 marks an important step in the history of the HIV/AIDS epidemic. Nearly 3 million people are now receiving anti-retroviral therapy (ART) in low- and middle-income countries, according to a new report jointly launched today by WHO, UNAIDS and UNICEF.

2 Jun 2008

Simple infection control intervention in elementary schools reduces student absenteeism

A study from researchers at Children's Hospital Boston published in Pediatrics found that a simple infection control intervention in elementary schools - disinfecting frequently-touched surfaces and using alcohol-based hand sanitizers - helped reduce illness-related student absenteeism.

2 Jun 2008